IMTX
Immatics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IMTX Profile
Immatics N.V.
A clinical-stage biotechnology company that developing T cell receptor-based immunotherapies for the treatment of cancer
Biological Technology
03/10/2020
07/02/2020
NASDAQ Stock Exchange
297
12-31
Common stock
Paul-Ehrlich-Strabe 15, 72076 Tübingen, Federal Republic of Germany
--
Immatics N.V., established on March 10, 2020, is a Dutch private limited liability company. The company is a biopharmaceutical company focused on the development of T-cell receptor-based immunotherapies.
